Stockreport

New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation

Pluristem Therapeutics, Inc.  (PSTI) 
Last pluristem therapeutics, inc. earnings: 2/6 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: pluristem.com
PDF Additional data from Pluristem’s Phase II IC study were presented at the 2018 American Heart Association Scientific Sessions HAIFA, Israel, Nov. 12, 2018 (GLOBE [Read more]